5-Aminosalicylate intolerance causing exacerbation in pediatric ulcerative colitis.

Area of Science:

• Pediatric Gastroenterology
• Inflammatory Bowel Disease Research
• Drug Hypersensitivity Studies

Background:

• 5-Aminosalicylate (5-ASA) is a primary treatment for ulcerative colitis (UC).
• 5-ASA intolerance can mimic disease flares, leading to inappropriate treatment escalation.
• Limited data exist on 5-ASA intolerance incidence, characteristics, and diagnosis in children.

Purpose of the Study:

• To determine the incidence of 5-ASA intolerance in pediatric UC patients.
• To describe the clinical features, disease course, and laboratory findings associated with 5-ASA intolerance.
• To identify diagnostic markers for 5-ASA intolerance.

Main Methods:

• Retrospective review of medical records for 80 pediatric UC patients.
• Analysis of patient demographics, clinical symptoms, and laboratory data.
• Evaluation of diagnostic test results, including drug-induced lymphocyte stimulation test (DLST).

Main Results:

• 13.8% (11/80) of pediatric UC patients were diagnosed with 5-ASA intolerance.
• The median onset of intolerance symptoms was 10 days after 5-ASA initiation (range: 4-20 days) in patients not on corticosteroids.
• Elevated C-reactive protein (CRP) and positive DLST (8/10 patients) were observed during exacerbations.

Conclusions:

• 5-ASA intolerance has a notable incidence in pediatric UC.
• Elevated CRP and positive DLST can support the diagnosis of 5-ASA intolerance.
• Further research is needed to refine diagnostic strategies for 5-ASA intolerance.